Yorhe(SZ:002795)2024-07-09 09:35Financial Performance Expectations - The company expects a net loss of between 74 million RMB and 47 million RMB for the first half of 2024, compared to a loss of 22.49 million RMB in the same period last year, representing a decline of 228.97% to 108.94%[8] - The expected net loss after deducting non-recurring gains and losses is between 75 million RMB and 48 million RMB, compared to a loss of 22.39 million RMB last year, indicating a decline of 234.95% to 114.37%[8] - The company's operating revenue is projected to be between 400 million RMB and 450 million RMB, down from 497.88 million RMB in the previous year[8] - The basic earnings per share are expected to be a loss of between 0.17 RMB and 0.11 RMB, compared to a loss of 0.05 RMB per share last year[8] Reasons for Performance Decline - The decline in performance is attributed to a decrease in overseas orders for valve fittings, lower pricing for some products to expand the market, and a significant increase in the price of raw materials such as copper rods, leading to a decrease in gross margin[16] - The medical business's operating revenue has also decreased compared to the same period last year, contributing to the decline in gross margin[16] - The photovoltaic cell business is burdened with high fixed costs, including depreciation of machinery and equipment and personnel salaries[16] Stock Incentive Plan - The company granted 22.36948 million restricted stock units to 53 incentive targets under the 2022 restricted stock incentive plan, with 11.18474 million units yet to be unlocked by June 30, 2024[3] - The estimated amortization cost for the restricted stock in the first half of 2024 is approximately 7.8666 million RMB, which will be recorded in management expenses[3] Caution in Financial Reporting - The company emphasizes the importance of cautious decision-making and awareness of investment risks due to the preliminary nature of the financial data provided[6]